{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:54:46Z","timestamp":1794959686979,"version":"4.9.1"},"reference-count":36,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In multiple myeloma (MM), advancements in treatments and toxicity management have enhanced survival rates. This, coupled with shifting age demographics in MM, necessitates an updated assessment of infection risks in MM patients compared to the general population. Using Swedish population-based registries, we investigated the incidence of infections in 8,672 Swedish symptomatic MM patients diagnosed 2008-2021 and 34,561 matched controls. Overall, MM patients had a 5-fold risk (hazard ratio [HR] =5.30; 95% confidence interval [CI]: 5.14-5.47) of developing a clinically significant infection compared to matched controls. Bacterial infections represented a 5-fold (HR=4.88; 95% CI: 4.70-5.07) increased risk, viral and fungal infections 7-fold compared to controls. The first year after MM diagnosis the risk of infections compared to controls was 7-fold (HR=6.95; 95% CI: 6.61-7.30) and remained elevated up to 5 years after the myeloma diagnosis. The risk of infection compared to controls remained 5-fold in MM patients with follow-up till 2022. Preceding MM diagnosis, the risk compared to matched controls was significantly increased up to 4 years before MM diagnosis (HR=1.16; 95% CI: 1.05-1.28). Among MM patients, 8% had died within 2 months of diagnosis and infection contributed to 32% of all deaths. After 1 year, 20% MM patients had died, and infection-related mortality was 27%. Our data constitute the largest population-based study to date on the risk of infections compared to the normal population in the era of modern MM therapies and confirms that infections still represent a major threat to patients and underscores importance of preventive strategies.<\/jats:p>","DOI":"10.3324\/haematol.2024.285645","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:45:17Z","timestamp":1721277917000},"page":"163-172","source":"Crossref","is-referenced-by-count":19,"title":["Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry"],"prefix":"10.3324","volume":"110","author":[{"given":"Cecilie Hveding","family":"Blimark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Einarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshtak","family":"Karma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Knut-Bojanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Larfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Villegas-Scivetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingigerdur","family":"Sverrisd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"71054","doi-asserted-by":"crossref","unstructured":"Binder M, Nandakumar B, Rajkumar SV. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022; 36(3):801-808.","DOI":"10.1038\/s41375-021-01453-5"},{"key":"71055","doi-asserted-by":"crossref","unstructured":"Brink M, Groen K, Sonneveld P. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer J. 2021; 11(11):178.","DOI":"10.1038\/s41408-021-00571-8"},{"key":"71056","doi-asserted-by":"crossref","unstructured":"Ludwig H, Kumar S. Prevention of infections including vaccination strategies in multiple myeloma. Am J Hematol. 2023; 98(Suppl 2):S46-S62.","DOI":"10.1002\/ajh.26766"},{"key":"71057","doi-asserted-by":"crossref","unstructured":"Augustson BM, Begum G, Dunn JA. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005; 23(36):9219-9226.","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"71058","doi-asserted-by":"crossref","unstructured":"Murakami H, Hayashi K, Hatsumi N. Risk factors for early death in patients undergoing treatment for multiple myeloma. Ann Hematol. 2001; 80(8):452-455.","DOI":"10.1007\/s002770100330"},{"key":"71059","doi-asserted-by":"crossref","unstructured":"Blimark C, Holmberg E, Mellqvist UH. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015; 100(1):107-113.","DOI":"10.3324\/haematol.2014.107714"},{"key":"71060","doi-asserted-by":"crossref","unstructured":"Blimark CH, Turesson I, Genell A. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018; 103(3):506-513.","DOI":"10.3324\/haematol.2017.178103"},{"key":"71061","doi-asserted-by":"crossref","unstructured":"Blimark CH, Vangsted AJ, Klausen TW. Outcome data from &gt;10000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022; 108(2):99-108.","DOI":"10.1111\/ejh.13707"},{"key":"71062","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Andersson E, Ekbom A. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011; 11:450.","DOI":"10.1186\/1471-2458-11-450"},{"key":"71063","doi-asserted-by":"crossref","unstructured":"Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish Prescribed Drug Register - a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016; 119(5):464-469.","DOI":"10.1111\/bcpt.12613"},{"key":"71064","doi-asserted-by":"crossref","unstructured":"Armitage JN, van der Meulen JH, Group obotRCoSC-mC. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. Br J Surg. 2010; 97(5):772-781.","DOI":"10.1002\/bjs.6930"},{"key":"71065","doi-asserted-by":"crossref","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J. The Swedish Cause of Death Register. Eur J Epidemiol. 2017; 32(9):765-773.","DOI":"10.1007\/s10654-017-0316-1"},{"key":"71066","doi-asserted-by":"crossref","unstructured":"Richardson PG, Sonneveld P, Schuster MW. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-2498.","DOI":"10.1056\/NEJMoa043445"},{"key":"71067","doi-asserted-by":"crossref","unstructured":"Lonial S, Dimopoulos M, Palumbo A. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7):621-631.","DOI":"10.1056\/NEJMoa1505654"},{"key":"71068","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"71069","doi-asserted-by":"crossref","unstructured":"Burns EA, Ensor JE, Anand K. Opportunistic infections in patients receiving daratumumab regimens for multiple myeloma (MM). Blood. 2021; 138(Suppl 1):4740.","DOI":"10.1182\/blood-2021-152068"},{"key":"71070","doi-asserted-by":"crossref","unstructured":"Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013; 8(5):e64354.","DOI":"10.1371\/journal.pone.0064354"},{"key":"71071","doi-asserted-by":"crossref","unstructured":"Miguel JS, Weisel K, Moreau P. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066.","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"71072","doi-asserted-by":"crossref","unstructured":"Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015; 171(1):100-108.","DOI":"10.1111\/bjh.13532"},{"key":"71073","doi-asserted-by":"crossref","unstructured":"Dumontet C, Hulin C, Dimopoulos MA. A predictive model for risk of early grade \u2265 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018; 32(6):1404-1413.","DOI":"10.1038\/s41375-018-0133-x"},{"key":"71074","doi-asserted-by":"crossref","unstructured":"Brioli A, Klaus M, Sayer H. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019; 98(3):713-722.","DOI":"10.1007\/s00277-019-03621-1"},{"key":"71075","doi-asserted-by":"crossref","unstructured":"Blimark CH, Turesson I, Genell A. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018; 103(3):506-513.","DOI":"10.3324\/haematol.2017.178103"},{"key":"71076","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012; 97(6):854-858.","DOI":"10.3324\/haematol.2011.054015"},{"key":"71077","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Bjorkholm M, Andersson TM. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica. 2009; 94(12):1714-1720.","DOI":"10.3324\/haematol.2009.010066"},{"key":"71078","doi-asserted-by":"crossref","unstructured":"Ludwig H, Meckl A, Engelhardt M. Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience. HemaSphere. 2021; 5(7):e597.","DOI":"10.1097\/HS9.0000000000000597"},{"key":"71079","doi-asserted-by":"crossref","unstructured":"Teh BW HS, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. Eur J Haematol. 2017; 98(2):149-153.","DOI":"10.1111\/ejh.12813"},{"key":"71080","doi-asserted-by":"crossref","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. Eur J Haematol. 2019; 102(2):182-190.","DOI":"10.1111\/ejh.13190"},{"key":"71081","doi-asserted-by":"crossref","unstructured":"Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk. 2021; 21(7):444-450.e3.","DOI":"10.1016\/j.clml.2021.02.002"},{"key":"71082","doi-asserted-by":"crossref","unstructured":"Raje NS, Anaissie E, Kumar SK. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022; 9(2):e143-e161.","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"71083","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Jacobus S, Callander NS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11(1):29-37.","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"71084","unstructured":"The Swedish Myeloma Group. The Swedish national guidelines in multiple myeloma 2024. 2024."},{"key":"71085","doi-asserted-by":"crossref","unstructured":"Holmstr\u00f6m MO, Gimsing P, Abildgaard N. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015; 90(4):e73-e74.","DOI":"10.1002\/ajh.23932"},{"key":"71086","doi-asserted-by":"crossref","unstructured":"Thidemann Andersen K, Klausen T, Abildgaard N. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: a study based on the nationwide Danish Multiple Myeloma Registry. Am J Haematol. 2017; 92(10):e611-e614.","DOI":"10.1002\/ajh.24857"},{"key":"71087","doi-asserted-by":"crossref","unstructured":"Caravita T, Offidani M, Siniscalchi A. Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations. Eur J of Haematol. 2012; 89(3):276-277.","DOI":"10.1111\/j.1600-0609.2012.01814.x"},{"key":"71088","doi-asserted-by":"crossref","unstructured":"Hsu P, Lin TW, Gau JP. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine (Baltimore). 2015; 94(50):e2305.","DOI":"10.1097\/MD.0000000000002305"},{"key":"71089","doi-asserted-by":"crossref","unstructured":"Moore KLF, Blimark CH, Vangsted AJ. P-167: Real-world elderly myeloma patients: improved survival despite more adverse risk factors than younger patients and RCT populations. A study on behalf of the Nordic Myeloma Study Group. Clin Lymphoma Myeloma Leuk. 2021; 21:S127-S128.","DOI":"10.1016\/S2152-2650(21)02294-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285645\/77901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285645\/77948","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11697\/77282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:55Z","timestamp":1794046015000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285645","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}